Acurable raises 11 million euros to expand home sleep apnea testing device globally
Acurable, a UK-based medical device company, announced it has raised 11 million euros ($10.8 million) in a Series A funding round led by Kibo Ventures.
Mundi Ventures, Comprador Holdings and Kindred Capital joined the bull run.
The company will use the funds to accelerate the international expansion of its first home sleep testing device, the AcuPebble SA100, which allows users to detect and monitor obstructive sleep apnea.
Acurable will also develop new products for chronic obstructive pulmonary disease (COPD), asthma and cardiovascular conditions.
The AcuPebble SA100 is launching in the UK and Spain in 2021. The company is looking to scale in two countries and expand in Europe and North America.
The device has received the CE marking in Europe for the automatic diagnosis of OSA at home. Last year, it received FDA License 510(k) in the US to sense, record, and interpret physiological signals, such as a patient’s respiratory pattern, while they sleep to prescreen for OSA.
SNAPSHOT . MARKET
Several companies offer home sleep apnea diagnostic testing, including one based in Israel Itamar Medicalexpand the capacity of the home sleep apnea diagnostic test line by 2021.
Its WatchPAT system attaches to the user’s index finger, chest, and wrist, measuring and recording peripheral arterial (PAT) signals, heart rate, oximetry, activity, body position, snoring, and movement. chest movement to identify cases of sleep apnea.
In 2021, it expanded its capabilities with SleePath, allowing users to record subjective data from its testing directly into the connected app, giving doctors a fuller picture through self-reported reports and sleep study data.
In 2020, Re-apply launched SleepCheck, an app to check for sleep apnea at home, and that same year the French company Withings released Sleep Analyzer, an under-mattress sleep monitoring pad that can be used to detect sleep apnea.
